Literature DB >> 27940233

Protective immune response in mice induced by a suicidal DNA vaccine encoding NTPase-II gene of Toxoplasma gondii.

Lina Zheng1, Yue Hu2, Qianqian Hua3, Fangjun Luo4, Guizhen Xie2, Xiangzhi Li2, Jiaxin Lin5, Yujing Wan2, Shoufeng Ren2, Changwang Pan6, Feng Tan7.   

Abstract

DNA-based alphaviral RNA replicon vectors, also called suicidal DNA vectors, have been employed to alleviate biosafety concerns attribution to its ability to induce apoptotic cell death of the transfected cells. Toxoplasma gondii nucleoside triphosphate hydrolase-II (TgNTPase-II), which facilitates the parasite to salvage purines from the host cell for survival and replication, have been demonstrated to be a potential vaccine candidate for toxoplasmosis. Herein, we evaluated the immunogenic potential of a suicidal DNA vaccine encoding TgNTPase-II gene, pDREP-TgNTPase-II, delivered intramuscularly in combination with electroporation. Immunization of mice with pDREP-TgNTPase-II elicited specific humoral responses, with high IgG antibody titers and a mixed IgG1/IgG2a response. The cellular immune response was associated with high level production of IFN-γ, IL-2, IL-10 cytokines and low level IL-4 production as well as the increase of the percentage of CD8+ T cells, indicating that a Th1 predominant response was elicited. Furthermore, mice vaccinated with this suicidal DNA vaccine displayed partial protection against acute infection with the virulent RH strain as well as chronic infection with PRU cyst, which shows 77.7% and 71.4% reduction in brain cyst burden in comparison to PBS and pDREP-eGFP control group, respectively. Based on the cellular and antibody responses, the suicidal DNA vaccine elicited a Th1-predominant immune response against T. gondii challenge.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alphavirus Semliki Forest virus (SFV); Nucleoside triphosphate hydrolase; Suicidal DNA vaccine; Toxoplasma gondii

Mesh:

Substances:

Year:  2016        PMID: 27940233     DOI: 10.1016/j.actatropica.2016.12.004

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  7 in total

Review 1.  REVIEW OF DNA VACCINE APPROACHES AGAINST THE PARASITE TOXOPLASMA GONDII.

Authors:  Rosalie C Warner; Ryan C Chapman; Brianna N Davis; Paul H Davis
Journal:  J Parasitol       Date:  2021-11-01       Impact factor: 1.276

Review 2.  Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development.

Authors:  Ki-Back Chu; Fu-Shi Quan
Journal:  Vaccines (Basel)       Date:  2021-04-21

Review 3.  Sixty Years (1957-2017) of Research on Toxoplasmosis in China-An Overview.

Authors:  Ming Pan; Congcong Lyu; Junlong Zhao; Bang Shen
Journal:  Front Microbiol       Date:  2017-09-25       Impact factor: 5.640

4.  Evaluation of Protective Immune Response Induced by a DNA Vaccine Encoding GRA8 against Acute Toxoplasmosis in a Murine Model.

Authors:  Jia-Qi Chu; Shuai Huang; Wei Ye; Xuan-Yan Fan; Rui Huang; Shi-Cai Ye; Cai-Yuan Yu; Wei-Yun Wu; Yu Zhou; Wei Zhou; Young-Ha Lee; Juan-Hua Quan
Journal:  Korean J Parasitol       Date:  2018-08-31       Impact factor: 1.341

5.  Immunization with a suicidal DNA vaccine expressing the E glycoprotein protects ducklings against duck Tembusu virus.

Authors:  Jingyu Tang; Zhuangli Bi; Mingyang Ding; Dongdong Yin; Jie Zhu; Li Zhang; Qiuhong Miao; Yingqi Zhu; Guijun Wang; Guangqing Liu
Journal:  Virol J       Date:  2018-09-14       Impact factor: 4.099

Review 6.  Plasmid DNA-based Alphavirus Vaccines.

Authors:  Kenneth Lundstrom
Journal:  Vaccines (Basel)       Date:  2019-03-08

7.  Immune responses and protection after DNA vaccination against Toxoplasma gondii calcium-dependent protein kinase 2 (TgCDPK2).

Authors:  Kai Chen; Jin-Lei Wang; Si-Yang Huang; Wen-Bin Yang; Wei-Ning Zhu; Xing-Quan Zhu
Journal:  Parasite       Date:  2017-11-09       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.